Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide and Everolimus in Relapsed/Refractory Multiple Myeloma
NCT01234974Phase 2Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Dec 2010
- Primary completion
- Dec 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR, everolimus in multiple myeloma (MM), sponsored by Penn State Health Milton S. Hershey Medical Center. Planned start Dec 2010; status: withdrawn.
02
Drugs
pasireotide LAReverolimus
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01234974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01234974.